Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects

Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects

Hannah Le,1 Kellie Ryan,1 Svea K Wahlstrom,2 Martine C Maculaitis,3 Oliver Will,4 Emily Mulvihill,5 Thomas W LeBlanc6 1US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA; 2US Patient Safety, AstraZeneca, Wilmington, DE, USA; 3Kantar, Health Division, New York, NY, USA; 4Kantar, Health Division,...

Full description

Bibliographic Details
Main Authors: Le H, Ryan K, Wahlstrom SK, Maculaitis MC, Will O, Mulvihill E, LeBlanc TW
Format: Article
Language:English
Published: Dove Medical Press 2021-01-01
Series:Patient Preference and Adherence
Subjects:
leukemia
lymphocytic
chronic
b-cell
progression-free survival
tumor lysis syndrome
oncologists
Online Access:https://www.dovepress.com/oncologist-and-patient-preferences-for-novel-agents-in-first-line-trea-peer-reviewed-article-PPA

Internet

https://www.dovepress.com/oncologist-and-patient-preferences-for-novel-agents-in-first-line-trea-peer-reviewed-article-PPA

Similar Items